Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients

References

• Piazza G, Fanikos J, Zayaruzny M, et al. Venous thromboembolic events in hospitalized medical patients. Thromb Haemost. 2009;102(3):505–510.
   PubMed Web of Science ®Google Scholar
• Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302(6778):709–711.
   PubMedGoogle Scholar
• Francis CW. Clinical practice. prophylaxis for thromboembolism in hospitalized medical patients [published correction appears in N engl j med. 2007 jul 12; 357(2):203]. N Engl J Med. 2007;356(14):1438–1444.
   PubMed Web of Science ®Google Scholar
• Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8–18.
   PubMed Web of Science ®Google Scholar
• Nafee T, Gibson CM, Travis R, et al. Machine learning to predict venous thrombosis in acutely ill medical patients. Res Pract Thromb Haemost. 2020;4(2):230–237. Published 2020 Jan 21.
   PubMed Web of Science ®Google Scholar
• Amin AN, Varker H, Princic Or N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231–238.
   PubMed Web of Science ®Google Scholar
• Rathbun S. Cardiology patient pages. The Surgeon General’s call to action to prevent deep vein DOI:10.1161/CIRCULATIONAHA.108.841403
   Google Scholar
• Korjian S, Daaboul Y, Halaby R, et al. Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: an Unmet Need. J Cardiovasc Pharmacol Ther. 2016 May;21(3):227–232. Epub 2015 Sep 3. PMID: 26341120.
   PubMed Web of Science ®Google Scholar
• Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800.
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–879.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–329.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ. Rationale supporting an “opt-out” policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. J Thromb Thrombolysis. 2013 Apr;35(3):371–374. PMID: 23386224.
   PubMed Web of Science ®Google Scholar
• Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969–977.
   PubMed Web of Science ®Google Scholar
• Spirk D, Stuck AK, Hager A, et al. Electronic alert system for improving appropriate thromboprophylaxis in hospitalized medical patients: a randomized controlled trial. J Thromb Haemost. 2017;15(11):2138–2146.
   PubMed Web of Science ®Google Scholar
• Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.
   PubMed Web of Science ®Google Scholar
• Scheres LJJ, Lijfering WM, Cannegieter SC. Current and future burden of venous thrombosis: not simply predictable. Res Pract Thromb Haemost. 2018 Apr 17;2(2):199–208. PMID: 30046722; PMCID: PMC6055567.
   PubMed Web of Science ®Google Scholar
• Cohen A, Spiro T, Buller H, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
   PubMed Web of Science ®Google Scholar
• Leizororovicz GSZ, Kakkar AK. Apixaban versus enoxaparin thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020;4(1):e59–e65. Published 2020 Mar 13.
   PubMedGoogle Scholar
• Gibson CM, Spyropoulos AC, Cohen AT, et al. The IMPROVEDD VTE Risk Score: incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017;1(1):e56–e65. Published 2017 Jun 28.
   PubMedGoogle Scholar
• Greene MT, Spyropoulos AC, Chopra V, et al. Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med. 2016;129(9):1001.e9-1001.e18.
   Web of Science ®Google Scholar
• Mahan CE, Liu Y, Turpie AG, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost. 2014;112(4):692–699.
   PubMed Web of Science ®Google Scholar
• Moumneh T, Riou J, Douillet D, et al. Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: A cohort study. J Thromb Haemost. 2020;18(6):1398–1407.
   PubMed Web of Science ®Google Scholar
• Darzi AJ, Karam SG, Spencer FA, et al. Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Adv. 2020;4(12):2557–2566.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014;167(3):335‐341.
   Web of Science ®Google Scholar
• Cohen A, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with Betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–544.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Goldhaber SZ, Cohen AT, et al. When academic research organizations and clinical research organizations disagree: processes to minimize discrepancies prior to unblinding of randomized trials. Am Heart J. 2017 Jul;189:1–8. Epub 2017 Mar 31. PMID: 28625365.
   PubMed Web of Science ®Google Scholar
• Lensing AW. Surrogate endpoints for the assessment of efficacy in venous thromboembolism treatment trials. Haemostasis. 1998;28(Suppl 3):127–130.
   PubMedGoogle Scholar
• Fanola CL, Norby FL, Shah AM, et al. Incident Heart Failure and Long-Term Risk for Venous Thromboembolism. J Am Coll Cardiol. 2020;75(2):148–158.
   PubMed Web of Science ®Google Scholar
• Moser KM, Fedullo PF, LitteJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis [published correction appears in JAMA 1994 Jun 22-29;271(24):1908]. JAMA. 1994;271(3):223–225.
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S–400S.
   PubMed Web of Science ®Google Scholar
• Dmitrienko A, D’Agostino RBS. Multiplicity Considerations in Clinical Trials. N Engl J Med. 2018;378(22):2115–2122.
   PubMed Web of Science ®Google Scholar
• Berkman SA. Multiplicity considerations in recent thrombosis related clinical trials, newsletter for the international society of evidence based medicine. 26(December):2019;
   Google Scholar
• Berkman SA. Competing Risk of Death in DVT trials in cancer patients, newsletter for the international society of evidence based medicine. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018;24(December):393–395.
   PubMedGoogle Scholar
• Gibson CM, Chi G, Halaby R, et al. APEX Investigators. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: an APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 Feb 14;135(7):648–655. Epub 2016 Nov 14. PMID: 27881569.
   PubMed Web of Science ®Google Scholar
• Chi G, Yee MK, Amin AN, et al. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 Jan 2;137(1):91–94. PMID: 29279341.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Korjian S, Chi G, et al. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: an APEX Trial Substudy. J Am Heart Assoc. 2017;6(7):e006015. Published 2017 Jul 11.
   PubMed Web of Science ®Google Scholar
• Yee MK, Nafee T, Daaboul Y, et al. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018 Jan;45(1):1–8. PMID:29188425 .
   PubMed Web of Science ®Google Scholar
• Cave B, Hough A, Dobesh PP. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients. Pharmacotherapy. 2018;38(6):597–609.
   PubMed Web of Science ®Google Scholar
• Chi G, Goldhaber SZ, Hull RD, et al. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: insights from the APEX Trial. Thromb Haemost. 2017;117(12):2389–2395.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Ageno W, Albers G, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118–1127.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Raskob G, Cohen A. Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial. Blood 2019; 134 (Supplement_1)Blood. 11/13/2019
   Google Scholar
• Ageno W, Lopes RD, Goldin M, et al. PB2391 Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older
   Google Scholar
• PB2393 Spyropoulos AC, Barnathan ES, Ageno W, et al. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial
   Google Scholar
• Spyropoulos AC, Ageno W, Albers GW, et al. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020;75(25):3140–3147.
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198–3225. PMID: 30482763; PMCID: PMC6258910.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ. Thromboembolism Prophylaxis for Patients Discharged From the Hospital: easier Said Than Done. J Am Coll Cardiol. 2020;75(25):3148–3150.
   PubMed Web of Science ®Google Scholar
• Shermock KM, Lau BD, Haut ER, et al. Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies. PLoS One. 2013;8(6):e66311. Published 2013 Jun 14.
   PubMed Web of Science ®Google Scholar
• Haut ER, Lau BD, Kraus PS, et al. Preventability of Hospital-Acquired Venous Thromboembolism. JAMA Surg. 2015;150(9):912–915.
   PubMed Web of Science ®Google Scholar
• Louis SG, Sato M, Geraci T, et al. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg. 2014;149(4):365–370.
   PubMed Web of Science ®Google Scholar
• Popoola VO, Tavakoli F, Lau BD, et al. Exploring the impact of route of administration on medication acceptance in hospitalized patients: implications for venous thromboembolism prevention. Thromb Res. 2017;160:109–113.
   PubMed Web of Science ®Google Scholar
• Barkoudah E, Piazza G, Hecht TEH, et al. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: an NATF Anticoagulation Action Initiative. Am J Med. 2020;133(Suppl 1):1–27.
   PubMedGoogle Scholar
• Petterson TM, Smith CY, Emerson JA, et al. Venous thromboembolism (VTE) incidence and VTE-associated survival among olmsted county residents of local nursing homes. Thromb Haemost. 2018;118(07):1316–1328.
   PubMedGoogle Scholar
• Spyropoulos AC, Lipardi C, Xu J, et al. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019;25:1076029619886022.
   Web of Science ®Google Scholar
• Klok FAK, MJHA VM, NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Apr 13; DOI:10.1016/j.thromres.2020.04.013
   Web of Science ®Google Scholar
• Llitjos JF, Leclerc M, Chochois C. High incidence of venous thromboembolic events in anticoagulated severe Covid 19 patients. J Thromb Haemost. 2020 Apr 22nd;18(7):1743–1746. (e pub ahead of print
   PubMed Web of Science ®Google Scholar
• Helms J, Tacquard C, Severge F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection. A multicenter prospective cohort study. Int Care M.
   Google Scholar
• Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19 [published online ahead of print, 2020 May 5]. J Thromb Haemost. 2020; DOI:10.1111/jth.14888
   Web of Science ®Google Scholar
• Chi G, Lee JJ, Jamil A, et al. Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. J Clin Med. 2020 Aug 3;9(8):2489.
   PubMed Web of Science ®Google Scholar
• Berkman SA, Tapson VF. methodological issues and controversies in Covid coagulopathy. journal of clinical and applied thrombosis and hemostasis 2020 July 26:107602962094539.
   Google Scholar
• Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine. 2020;24:100434.
   PubMedGoogle Scholar
• Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128. doi:10.1056/NEJMoa2015432. Epub 2020 May 21. PMID: 32437596; PMCID: PMC7412750.
   Google Scholar
• Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9–16. PMID: 12814980.
   PubMed Web of Science ®Google Scholar
• Chi G, Gibson CM, Kalayci A, et al. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 Apr;45(4):477–487. Epub 2019 Feb 18. PMID: 30778649.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094–1099. Epub 2020 Apr 27. PMID: 32220112.
   PubMed Web of Science ®Google Scholar
• Heit JA, Crusan DJ, Ashrani AA, et al. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood. 2017;130(2):109–114.
   PubMed Web of Science ®Google Scholar
• Amin A, Varker H, Princic N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231–238.
   PubMed Web of Science ®Google Scholar
• Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167(14):1471–1475.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Spyropoulos AC, Cohen AT, et al. Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: insights from the Magellan Study. Blood. 2019;134(Supplement_1):163.
   Google Scholar
• Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec;118(12):2046-2052. doi: 10.1055/s-0038-1675606. Epub 2018 Nov 12. PMID: 30419597.
   Google Scholar
• Engelen M. Low incidence of venous thromboembolism in patients discharged after overnight hospitalization oral presentation IST H. 2020;
   Google Scholar
• Roberts LN, Whyte MB, Georgiou L, et al. Post-discharge venous thromboembolism following hospital admission with COVID-19 [published online ahead of print, 2020 Aug 3]. Blood. 2020;136(11):1347–1350. blood.2020008086.
   Web of Science ®Google Scholar
• Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 Sep 10;136(11):1342–1346. PMID: 32766883; PMCID: PMC7483433.
   PubMed Web of Science ®Google Scholar
• Flaczyk A, Rosovsky RP, Reed CT, et al. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit Care. 2020 Sep 16;24(1):559. PMID: 32938471; PMCID: PMC7492793.
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033–2040. PMID: 32339221; PMCID: PMC7273827.
   PubMed Web of Science ®Google Scholar